Stacy Lindborg - Brainstorm Cell CoChief Officer
| BCLI Stock | USD 1.41 0.13 8.44% |
Executive
Stacy Lindborg is CoChief Officer of Brainstorm Cell Therapeutics
| Age | 54 |
| Address | 1325 Avenue of Americas, New York, NY, United States, 10019 |
| Phone | 201 488 0460 |
| Web | https://www.brainstorm-cell.com |
Stacy Lindborg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stacy Lindborg against Brainstorm Cell stock is an integral part of due diligence when investing in Brainstorm Cell. Stacy Lindborg insider activity provides valuable insight into whether Brainstorm Cell is net buyers or sellers over its current business cycle. Note, Brainstorm Cell insiders must abide by specific rules, including filing SEC forms every time they buy or sell Brainstorm Cell'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stacy Lindborg over a week ago Acquisition by Stacy Lindborg of 75000 shares of Imunon at 0.8651 subject to Rule 16b-3 | ||
Stacy Lindborg over six months ago Acquisition by Stacy Lindborg of 100000 shares of Brainstorm Cell at 7.67 subject to Rule 16b-3 | ||
Stacy Lindborg over six months ago Acquisition by Stacy Lindborg of 200 shares of Brainstorm Cell at 10.0 subject to Rule 16b-3 |
Brainstorm Cell Management Efficiency
The company has return on total asset (ROA) of (2.1584) % which means that it has lost $2.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.219) %, meaning that it created substantial loss on money invested by shareholders. Brainstorm Cell's management efficiency ratios could be used to measure how well Brainstorm Cell manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Brainstorm Cell's Return On Capital Employed is increasing as compared to previous years. The Brainstorm Cell's current Return On Equity is estimated to increase to 3.34, while Return On Tangible Assets are projected to decrease to (3.86). As of now, Brainstorm Cell's Total Assets are increasing as compared to previous years. The Brainstorm Cell's current Other Current Assets is estimated to increase to about 661.7 K, while Non Current Assets Total are projected to decrease to under 1.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yalonda JD | Generation Bio Co | 53 | |
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Yael Fellous | Protalix Biotherapeutics | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Jeffrey Arcara | Corvus Pharmaceuticals | N/A | |
| FASCP MD | Inozyme Pharma | 70 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| JD Esq | Passage Bio | 61 | |
| Nicole Esq | HCW Biologics | N/A | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Christian Vasquez | Bioatla | 48 | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Bin Zhang | Bioatla | N/A | |
| Stephen MBA | Inozyme Pharma | 66 | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Kevin Conway | Generation Bio Co | N/A | |
Management Performance
| Return On Equity | -11.22 | ||||
| Return On Asset | -2.16 |
Brainstorm Cell Ther Leadership Team
Elected by the shareholders, the Brainstorm Cell's board of directors comprises two types of representatives: Brainstorm Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainstorm. The board's role is to monitor Brainstorm Cell's management team and ensure that shareholders' interests are well served. Brainstorm Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainstorm Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antal PearlLendner, VP Counsel | ||
| Daniel Offen, Chief Advisor | ||
| Ibrahim MD, Executive Officer | ||
| Mary Turner, Senior Affairs | ||
| Hartoun Hartounian, Executive COO | ||
| Netta BlondheimShraga, Senior Development | ||
| Stacy Lindborg, CoChief Officer | ||
| Ralph Kern, COO and Chief Medical Officer | ||
| Chaim Lebovits, President CoCEO | ||
| PharmD MBA, Ex COO | ||
| Yael Gothelf, Vice Affairs | ||
| Irit DSc, CoFounder Board | ||
| William White, Senior Pricing | ||
| Uri Yablonka, COO and Director |
Brainstorm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainstorm Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.22 | ||||
| Return On Asset | -2.16 | ||||
| Current Valuation | 9.46 M | ||||
| Shares Outstanding | 5.7 M | ||||
| Shares Owned By Insiders | 20.83 % | ||||
| Shares Owned By Institutions | 12.49 % | ||||
| Number Of Shares Shorted | 110.85 K | ||||
| Price To Earning | (16.00) X | ||||
| Price To Book | 65.82 X | ||||
| EBITDA | (16.93 M) |
Currently Active Assets on Macroaxis
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.